These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Specific serological reactions and factors in the natural resistance of the body in latent syphilis]. Budanova NP; Orlina EA Vestn Dermatol Venerol; 1981 Dec; (12):41-3. PubMed ID: 7036570 [No Abstract] [Full Text] [Related]
6. [Continuous method of treatment of recurrent and early latent syphilis]. Glavinskaia TA; Frigo IV; Novikova SI; Pavlovskaia VE; Rezaĭkina AV Vestn Dermatol Venerol; 1983 Apr; (4):29-33. PubMed ID: 6868814 [No Abstract] [Full Text] [Related]
7. [Visceral syphilis based on the data of the Moscow District Scientific-Research Institute]. Zlatkina AR Vestn Dermatol Venerol; 1966 Dec; 40(12):27-31. PubMed ID: 4233574 [No Abstract] [Full Text] [Related]
8. [Characteristics of the state of humoral and cellular immunity in patients with latent syphilis]. Nesterenko GB; Zakharov VK Vestn Dermatol Venerol; 1983 Oct; (10):67-71. PubMed ID: 6606907 [No Abstract] [Full Text] [Related]
9. [Immunologic aspects of the pathogenesis of latent and seroresistant forms of syphilis]. Shetsiruli LT; Gogebashvili NV; Toniia KS Vestn Dermatol Venerol; 1989; (5):55-8. PubMed ID: 2528248 [TBL] [Abstract][Full Text] [Related]
11. The fluorescent treponemal antibody-absorption test (FTA-ABS) in treated latent and late syphilis. Förström L; Lassus A Acta Derm Venereol; 1969; 49(3):326-31. PubMed ID: 4184281 [No Abstract] [Full Text] [Related]
12. Comparison of early and late latent syphilis--Colorado, 1991. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 1993 Mar; 42(8):155-7. PubMed ID: 8437546 [TBL] [Abstract][Full Text] [Related]
13. [The rate of detecting Chlamydia in male homosexuals with syphilis]. Borisenko KK; Delektorskiĭ VV; Shakirov MT; Kubanova AA; Tishchenko EL; Toporovskiĭ LM Vestn Dermatol Venerol; 1990; (6):52-4. PubMed ID: 2220064 [TBL] [Abstract][Full Text] [Related]
15. [The B link in the immunity of patients with infectious forms of syphilis]. Manuĭlova LA; Fedotov VP; Logunov VP Vestn Dermatol Venerol; 1984 Mar; (3):22-6. PubMed ID: 6610257 [No Abstract] [Full Text] [Related]
16. [Nonspecific immobilizing activity factor (NIA) in the blood serum of donors and persons having sexual contact with syphilis patients]. Borisenko KK; Sazonova LV; Sturza VE Vestn Dermatol Venerol; 1988; (11):19-22. PubMed ID: 3239223 [No Abstract] [Full Text] [Related]
17. [Characteristics of current latent syphilis]. Vasil'ev TV; Toporovskiĭ LM; Egorov GI; Ovsiannikov LM; Shibanov VA Vestn Dermatol Venerol; 1971 Jul; 45(7):45-50. PubMed ID: 5134847 [No Abstract] [Full Text] [Related]
18. [Use of splenin for the purpose of immunocorrection in patients with seroresistance following syphilis treatment]. Bakhmet'eva TM; Lonshakov IuI; Petrova IV Vestn Dermatol Venerol; 1988; (10):38-42. PubMed ID: 3223051 [No Abstract] [Full Text] [Related]
20. [Statistical considerations on verified cases of latent syphilis among the patients of 2 hospitals of Genoa in 1968]. Di Rocco P Ig Mod; 1969; 62(9):699-704. PubMed ID: 5401526 [No Abstract] [Full Text] [Related] [Next] [New Search]